LICENSE AGREEMENT by and between ALTUS PHARMACEUTICALS INC. and CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. DATED FEBRUARY 20, 2009 Portions of this Exhibit are omitted and have been filed separately with the Secretary of the Commission pursuant to...License Agreement • May 11th, 2009 • Altus Pharmaceuticals Inc. • Biological products, (no disgnostic substances) • Massachusetts
This License Agreement (this “Agreement”), is made as of February 20, 2009 (the “Effective Date”), by and between Altus Pharmaceuticals Inc., a Delaware corporation (“Altus”), and Cystic Fibrosis Foundation Therapeutics, Inc., a Maryland corporation (“CFFT”) and collectively, with Altus, the “Parties,” and each a “Party”).
AMENDMENT TO TERMINATION AGREEMENTTermination Agreement • May 11th, 2009 • Altus Pharmaceuticals Inc. • Biological products, (no disgnostic substances)
This Amendment to Termination Agreement (the “Amendment”) dated as of May 7, 2009 (the “Effective Date”) is an amendment to the Termination Agreement dated as of June 7, 2007 (the “Termination Agreement”), which in turn was a termination of the Development, Commercialization and Marketing Agreement (the “Agreement”) dated as of December 23, 2002 by and between Altus Pharmaceuticals Inc. (the successor in interest to Altus Biologics Inc.), a Delaware corporation, with its principal office at 610 Lincoln Street, Waltham, MA 02451 USA (“ALTUS”) and Dr. Falk Pharma GmbH, a German corporation, with its principal office at Leinenweberstrasse 5, 79041 Freiberg Germany (“FALK”).
